Text Size

Vouchers vs. Prizes for Methadone Patients - 1

This study has been completed.
Sponsor:
Collaborator:
University of Connecticut Health Center
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00249522
First received: November 3, 2005
Last updated: May 23, 2008
Last verified: May 2008
History of Changes
  Purpose

The purpose of this study is to compare voucher-based contingency management (CM) procedures to a lower-cost CM system that provides opportunities to win prizes. Cocaine-dependent outpatients are randomly assigned to (a) standard treatment, (b) standard treatment plus voucher CM for abstinence, defined by negative breath and urinalysis test results, or (c) standard treatment plus prize CM for abstinence, defined by negative breath and urinalysis test results. Urine and breath samples are collected 3x/week during Weeks 1-3, 2x/week during Weeks 4-6 and 1x/week during Weeks 7-12. Follow-up interviews are conducted 1,3,6 and 9 months following intake during which substance use and psychosocial functioning are assessed.


Condition Intervention
Substance Abuse
 Behavioral: Contingency management

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Vouchers vs. Prizes for Methadone Patients

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Drug use [ Time Frame: baseline and each follow-up ] [ Designated as safety issue: No ]

Enrollment: 76
Study Start Date: August 2003
Study Completion Date: January 2006
Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • age > 18 years
  • current DSM-IV diagnosis of cocaine dependence
  • maintained on a stable dose of methadone for >1 month
  • willing to sign informed consent
  • English speaking

Exclusion criteria:

  • serious, uncontrolled psychiatric illness (e.g., acute schizophrenia, bipolar disorder, or substantial suicide risk) on the basis of history or medical examination
  • dementia (<23 on the Mini Mental State Exam)
  • in recovery from pathological gambling as determined by DSM-IV criteria
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00249522

Locations
United States, Connecticut
University of Connecticut Health Center
Farmington, Connecticut, United States, 06030 2103
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
University of Connecticut Health Center
Investigators
Principal Investigator: Nancy Petry, Ph.D. University of Connecticut Health Center
  More Information

No publications provided

Responsible Party: Nancy Petry, Ph.D., UConn Health Center
ClinicalTrials.gov Identifier: NCT00249522     History of Changes
Other Study ID Numbers: NIDA-13444-1, R01-13444-1
Study First Received: November 3, 2005
Last Updated: May 23, 2008
Health Authority: United States: Federal Government
United States: Institutional Review Board

Keywords provided by National Institute on Drug Abuse (NIDA):
contingency management
substance abuse treatment

Additional relevant MeSH terms:
Substance-Related Disorders
Mental Disorders
Methadone
Analgesics, Opioid
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
 Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Depressants
Antitussive Agents
Respiratory System Agents
Narcotics

ClinicalTrials.gov processed this record on May 23, 2013